RIPK3 and colonic neoplasm: Additional research corroborated the significant decrease in RIPK3 expression in human CRC tissues relative to the adjacent normal tissues [10–13], with this downregulation associated with adverse clinicopathological parameters, such as T stage, M stage, and AJCC stage [10], and impaired responses of colon cancer cells to necroptosis inducers [9].